{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:12:41Z","timestamp":1788718361965,"version":"build-2803163510"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Alpelisib is a recently approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. It has been associated with alopecia and rash, but there are no documented cases of Stevens\u2013Johnson Syndrome (SJS) associated with this drug. Here, we detail the first case of SJS associated with alpelisib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>Our patient is a 60-year-old woman with a past medical history of metastatic hormone receptor-positive (ER+ 80% and PR+ 1%), HER2-negative metastatic breast cancer who presented with acute odynophagia, fevers, and diffuse body rash after receiving her first doses of alpelisib and fulvestrant in the preceding days. She presented to the emergency department after developing a whole-body rash and severe ulceration of her buccal mucosa. She was started on methylprednisolone with remarkable improvement in symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case report details the only report of SJS following alpelisib treatment. Immediate cessation of drugs and initiation of steroids are the cornerstone of treatment. Patients who experience such side effects will have to be monitored closely for long-term sequelae associated with SJS, including cutaneous, ocular, and oral sequelae, all of which can profoundly affect the quality of life for cancer patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.954027","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T05:28:41Z","timestamp":1664342921000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case report: Alpelisib-induced Stevens\u2013Johnson syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Christine Jane","family":"Kurian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Kamel","family":"Abou Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1813904\/SUPPL_FILE\/NEJMOA1813904_DATA-SHARING.PDF","article-title":"Alpelisib for PIK3CA -mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/J.JID.2016.03.023","article-title":"Morbidity and mortality of stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S347522","article-title":"Clinical commentary review sulfonamide hypersensitivity: Fact and fiction","volume":"14","author":"Khan","year":"2022","journal-title":"Drug Healthc Patient Saf"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/S12016-017-8654-Z","article-title":"Current perspectives on stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202601006","article-title":"Cephalexin-induced stevens-johnson syndrome","volume":"26","author":"Murray","year":"1992","journal-title":"Ann Pharmacother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2018.11.018","article-title":"Allopurinol-induced stevens-Johnson syndrome CASE PRESENTATION","volume":"357","author":"Gupta","year":"2019","journal-title":"Am J Med Sci"},{"key":"B7","first-page":"96","article-title":"Lamotrigine and stevens-Johnson syndrome prevention","volume":"51","author":"Edinoff","year":"2021","journal-title":"Psychopharmacol Bull"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDJ126","article-title":"Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy","volume":"17","author":"Curigliano","year":"2006","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/S40265-019-01161-6","article-title":"Alpelisib: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B10","unstructured":"Dosing | PIQRAY\u00ae (alpelisib) tablets"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA Approval summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5376476","article-title":"Anticancer drugs induced severe adverse cutaneous drug reactions: An updated review on the risks associated with anticancer targeted therapy or immunotherapies","author":"Ng","year":"2018","journal-title":"J Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.954027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T05:28:46Z","timestamp":1664342926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.954027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":12,"alternative-id":["10.3389\/fonc.2022.954027"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.954027","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"article-number":"954027"}}